<SEC-DOCUMENT>0001178913-11-002590.txt : 20110913
<SEC-HEADER>0001178913-11-002590.hdr.sgml : 20110913
<ACCEPTANCE-DATETIME>20110913070243
ACCESSION NUMBER:		0001178913-11-002590
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20110913
FILED AS OF DATE:		20110913
DATE AS OF CHANGE:		20110913

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COMPUGEN LTD
		CENTRAL INDEX KEY:			0001119774
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30902
		FILM NUMBER:		111086858

	BUSINESS ADDRESS:	
		STREET 1:		72 PINCHAS ROSEN ST
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			69512
		BUSINESS PHONE:		011-972-3-765-8585

	MAIL ADDRESS:	
		STREET 1:		72 PINCHAS ROSEN ST
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			69512
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk1110422.htm
<DESCRIPTION>6-K
<TEXT>
<html>
<head>
    <title>zk1110422.htm</title>
    <!--Licensed to: zk Global-->
    <!--Document Created using EDGARizer 2020 5.4.0.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FORM 6-K</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Washington, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Report of Foreign Private Issuer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">for the month of September 2011</font><br>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 16pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 16pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Compugen Ltd.</font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Translation of registrant's name in English)</font><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">72 Pinchas Rosen Street, Tel-Aviv 69512, Israel</font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Address of principal executive offices)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 28.35pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Form 20-F&#160;<font style="DISPLAY: inline;" face="Wingdings">x</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form 40-F <font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 28.35pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 28.35pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On September 13, 2011, Compugen Ltd. (the "Registrant") issued a Press Release, filed as Exhibit 1 to this Report on Form 6-K, which is hereby incorporated by reference herein.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 28.35pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">SIGNATURE</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 28.35pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div>
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold"> </font></font>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: normal">Compugen Ltd.</font></font></font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: normal">(Registrant)</font></font></font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="50%" style="BORDER-BOTTOM: #ffffff solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td valign="top" width="3%" style="BORDER-BOTTOM: #ffffff solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By: </font></div>
</td>
<td align="left" nowrap valign="top" width="35%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/&#160;Ms. Dikla Czaczkes Axselbrad</font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: #ffffff solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" nowrap valign="bottom" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Title:&#160;Chief Financial Officer</font></font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date: September 13, 2011</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>exhibit_1.htm
<DESCRIPTION>EXHIBIT 1
<TEXT>
<html>
<head>
    <title>exhibit_1.htm</title>
    <!--Licensed to: zk Global-->
    <!--Document Created using EDGARizer 2020 5.4.0.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-WEIGHT: bold; TEXT-DECORATION: underline">Exhibit 1<br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><img src="compugen_bw.jpg" alt=""><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 13pt; FONT-WEIGHT: bold">Compugen Announces Validation of Two Immune System</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 13pt; FONT-WEIGHT: bold">&#160;Modulating Drug Candidates</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Novel immunomodulatory proteins demonstrate</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">significant therapeutic potential&#160;&#160;for autoimmune diseases</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">New drug candidates based on two B7/CD28-like proteins discovered</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">through use of Compugen&#8217;s Protein Family Members Discovery Platform</font><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Tel Aviv, Israel and New York City, Sept. 13, 2011 --- Speaking today at the&#160;Rodman &amp; Renshaw Annual Global Investment Conference in New York City, Martin Gerstel, chairman of Compugen Ltd. (NASDAQ: CGEN), reviewed the current status of the Company and announced the validation of two therapeutic product candidates, CGEN-15021 and CGEN-15091, in various autoimmune disease animal models. These two molecules are soluble proteins based on two B7/CD28-like proteins recently discovered by Compugen.&#160;&#160;In view of its key role in modulating immune response, the B7/CD28 family of proteins is of high interest in medical research and to the pharmaceutical industry, and these newly discovered molecules share key
characteristics with this protein family.&#160;&#160;In addition to the potential use of CGEN-15021 and CGEN-15091 as protein therapeutics for multiple autoimmune diseases, the two proteins they are based on are predicted to have utility as drug targets for monoclonal antibody therapy in oncology.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">CGEN-15021 and CGEN-15091 are both soluble fusion proteins, each combining the extracellular domain of one of the newly discovered B7/CD28-like proteins and an Fc antibody fragment. Fusion to an Fc antibody fragment is an established methodology to create soluble long-acting therapeutic proteins. The results being announced today relate to the recent validation of CGEN-15021 in animal disease models of both multiple sclerosis and rheumatoid arthritis, and of CGEN-15091 in an animal disease model of multiple sclerosis. In each of these disease models, the Compugen fusion proteins demonstrated dramatic therapeutic effects in ameliorating disease symptoms. In addition, in earlier in vitro experiments, CGEN-15021 and
CGEN-15091 exhibited inhibition of T cell activation, confirming their predicted role in the modulation of the immune system.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In his presentation, (which has been posted on Compugen&#8217;s website: www.cgen.com), Mr. Gerstel stated, &#8220;The discovery process for these two immunomodulatory proteins is an excellent example of the power and uniqueness of&#160;&#160;the broad based scientific infrastructure for predictive discovery that has been established at Compugen over the past decade. This infrastructure now allows the rapid development of accurate in silico capabilities for the prediction of innovative therapeutic solutions in selected areas of unmet medical need.&#160;&#160;In this case, we initially directed these capabilities to the B7/CD28 protein family, a protein family of very high industry interest due to its key role in
regulating immune responses, and one with significant therapeutic potential in major pathological conditions, such as autoimmune diseases, transplantation and cancer.&#8221;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Mr. Gerstel continued, &#8220;Within approximately six months, we had integrated multiple components of our infrastructure capabilities to develop the Protein Family Members Discovery Platform, which during its initial discovery process, predicted nine new proteins sharing characteristics with the B7/CD28 protein family. The first three of these nine, consisting of&#160;&#160;the previously disclosed CGEN-15001 which is currently moving forward in our Pipeline Program, and the two proteins for which positive in vivo results are being announced today, have now been validated in established animal disease models. In addition, we subsequently extended this discovery capability beyond the B7/CD28 family, as well as
developing additional capabilities for the discovery of other types of immune related proteins, some of which are now beginning the validation process.&#8221;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Mr. Gerstel continued, &#8220;With respect to today&#8217;s disclosure, the in vitro validation experiments and the in vivo study in a multiple sclerosis animal model of CGEN-15021 and CGEN-15091 were part of Compugen&#8217;s long-term research agreement with Prof. Stephen Miller&#8217;s laboratory at Northwestern University. The in vivo validation of CGEN-15021 in a rheumatoid arthritis model was conducted at Dr. Richard Williams&#8217; laboratory at the Kennedy Institute of Rheumatology, Oxford University. Having long-term relationships with leading scientists at academic laboratories with well established assays and animal models, enables Compugen to quickly and efficiently validate its new
discoveries.&#8221;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Mr. Gerstel concluded, &#8220;We enthusiastically look forward to the further development of these very attractive drug candidates, and to the ongoing application of our unique capabilities to additional areas of unmet medical need.&#8221;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">About the B7/CD28 Protein Family of positive and negative co-stimulatory proteins</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Members of the B7/CD28 families have been intensively studied over the past decade and have brought much excitement to the field of immune regulation. The activation and development of an adaptive immune response is initiated by the engagement of a T-cell antigen receptor with an antigenic peptide-MHC complex. The outcome of this engagement is determined by both positive and negative co-stimulatory signals, generated mainly by the interaction between members of the B7 family ligands and their receptors, members of the CD28 family. A growing body of evidence indicates that the dysfunction of immune regulation contributes to the development of autoimmune diseases.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Positive and negative co-stimulatory pathways play critical roles in immune regulation and are considered potential targets for modulating chronic inflammation in autoimmune diseases. To date, one soluble recombinant fusion protein that selectively blocks the co-stimulatory signal mediated by the prototype B7/CD28 pathway has been cleared for marketing in the U.S. for the treatment of moderate to severe rheumatoid arthritis, and is in clinical trials for other autoimmune indications. In addition, a number of clinical and preclinical studies for therapeutic agents targeting these protein families are underway at various companies.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">2&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">About Compugen</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Compugen is a leading therapeutic product candidate discovery company, currently focused on biologics-based therapy to address important unmet needs in the fields of immunology and oncology, either for Compugen or its partners. Unlike traditional high throughput trial and error experimental based drug candidate discovery, Compugen&#8217;s discovery efforts are based on systematic and continuously improving in silico (by computer) product candidate prediction and selection followed by experimental validation, with selected product candidates being advanced in its Pipeline Program to the pre-IND stage. Compugen&#8217;s in silico predictive models utilize a broad and continuously growing infrastructure of proprietary
scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities. The Company&#8217;s business model primarily involves collaborations covering the further development and commercialization of Compugen-discovered product candidates and various forms of &#8220;discovery on demand&#8221; arrangements, in both cases providing Compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. In 2002, Compugen established an affiliate, Evogene Ltd. (www.evogene.com) (TASE: EVGN.TA), to utilize certain of the Company&#8217;s in silico predictive discovery capabilities in agricultural biotechnology. For additional information, please visit Compugen&#8217;s corporate website at www.cgen.com</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This press release may contain &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as &#8220;may&#8221;, &#8220;expects&#8221;, &#8220;anticipates&#8221;, &#8220;believes&#8221;, and &#8220;intends&#8221;, and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact
of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are identified and more fully explained under the heading &#8220;Risk Factors&#8221; in Compugen&#8217;s annual reports filed with the Securities and Exchange Commission.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Company contact:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Tsipi Haitovsky</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Global Media Liaison,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Compugen Ltd.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Tel: +972-52-598-9892</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">E-mail: tsipih@netvision.net.il</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><br>
3</div>
</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>compugen_bw.jpg
<TEXT>
begin 644 compugen_bw.jpg
M_]C_X``02D9)1@`!``$`E@"6``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``0"`P,#`@0#`P,$!`0$!@H&!@4%!@P)"0<*#PT/#PX-
M#@X0$A<4$!$6$0X.%!P5%A@9&AL:$!0='QT:'Q<:&AD!!`0$!@4&#`8&#!D1
M#A$9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9
M&1D9&1D9&?_$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`%$`U@,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/OZ@`H`;O7.WOV'K0!Q/Q+\>ZOX5U&"RTSX<>*O$YD0N\VE
M10^7%Z`M(ZY/TH`\;^(`@\:>(7UG7_@=\:FN&0($M-?DM8D4=ECANU0?ES0!
MB2^%O#B0,TGP-^.BHHRQ?Q==!0/<F^P!0!RGC>UM+;3H?^$'^!OQ%U.^ED"M
M'J/Q(GMT`[;=EZS,Q.,`"@#Z`_9S^#^A^'K6P\;ZUX.&F>,I;8QNMSKEWJQL
M48Y,<<MPS%6(QNV@#.1DB@#V*@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"
M@`H`*`"@`H`*`/"OCC\3M+U3[?X//A_XOVB6ESL?5/"NG21&;8>0DP&=A/=<
M9QUQ0!Y>+GPX/^6W[57T^U7G^-`#EG\.$<2_M4_^!=Y_C0!Y_P#$B]UC5/[0
M\/\`_"J/VBO$WAZX'EG^T_%<\*W2?[<)C;C/8DT`;7[%?P9\":G\9[76;SX`
M^,O!TOAH+J-I>:]K+7$#SJV$`C,2Y93\X.>"H-`'W30`4`%`!0`4`%`!0`4`
M%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`$=U&TMM)&DK0LZE5D3&5)'49XXH`^4
M?&]W'X2\4W?AW6OVEOC+'?6+!9%M_"K7$?(##;)'9,K#!'()H`R/^$KT?_HY
MOXV_^$;/_P#(%`%;6=>\.ZEHUYIE[^TK\;IK:\A>&:(>#[A"Z,,$!A8@KD$C
M((H`^=SH7@@$JNC_`+3CA3C<@AP?<90'\P*`/3?V5/'?AGX1_$<ZM;>%?C[=
MVNIQK97?]NV4=Q;P1EU/G%8T\SY.3A>2">"<"@#]!].NH+VP@O;60207$:R1
MNO1E(R#0!-0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`&;
MXNL=4U'P]=66BZT^C7TJ8AOT@28PMV.QQM;Z&@#YN^(WQ%O/`/BN?PSXP_:M
MATG5;94:2VG\'1YVL,J00A!!'<$]".H-`&%_POC0_P#H\>Q_\(Y/_C=`',>/
M_'G@_P`97%I+J'[;6HV+V@94_LC1'L@P."=^Q1NZ<9Z<T`>.M\5?#Z2.B_&W
M]HR3:Q&^+3[5D;'=3]JY![&@#TS]E3]HKPQX5^)EIIM[XZ^,7B*SUZ>.R:#Q
M+HUMY,,KL%23S5N&=`"><`Y!Z<4`??M`!0`4`%`!0`4`%`!0`4`%`!0`4`%`
M!0`4`%`!0`4`%`!0`4`%`'@7QI^*MO\`\)6MKX+_`&A?A-X;CLD,%[9:S)%<
M3B<,<\B==N!QM(SG-`'(?\+1\6?]'7_`K_P'C_\`DF@!5^*'BLG!_:O^!6.X
M^SQ]/_`F@#PKXG?'K5;SQK>,G[7[:=]G(MS%X?\`"TALV*\%T)<[@?[P.#0!
MH?`KQUXP^('Q8T/POH/[6_B76KFZN5DDLE\,O$)(D.^3<Y;"#:",GUH`_1"@
M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`R=5\4^&=+OFLM2\
M1Z39W*`%H+B\CC=0>A*D@\T`>=_$CQQXODUI8_`7BOX5Q::JX9];U-VED;'.
M%CX`_$Y]J`.`9?&VXDS?LWY/)SO_`,*`.2^(WQ*7P&\,?B?7/V=+>6?E(;:S
MN+E\>I6-3@>YH`\Z\;_'2TUB&WCT'XK?!;PPT1)DEL_"D]PTOH#YT+``>PS[
MT`:7PB3XR_%&\FM/`'QL^'NK_9P3)/'X&1((SZ&1K4+N]LYH`^P?@=X'U+P=
MX3AB\2:Q9:[X@D&;O4K?2K>Q4YYV(D*+\@/3=DGK[``[B@`H`*`"@`H`*`"@
M`H`*`"@`H`*`"@`H`*`"@`H`*`"@#SGXC>,/B1IOB)[/P;X)\,ZSIZ(-UWJ/
MB;[$^_\`B41B"3@>I(^E`'DNI>$M4U'49]0U+]E[X,WMY=2&2:YN?$D<DDC'
MJ69K$DGW)H`KS>"6BA>67]E3X'QQQJ6=V\0P@*!U)/V#I0!X?\2]?T/4KR!?
M!.E?LJ^$H(AB9+BXM=2DF;_>DME"K[!<^_:@#'\-6/C/7M>M=%T#6?V6]1U.
M_D\JWM+/1K!Y97ZX`$'I0!],?L__`+-^K(PU/XR:-\,+D@,JZ)H?A"QCC]`T
MEQY>\]<[5"]!DGD4`?1/AO1=(\/:/#I6A:79:98VXQ':V4"PQ)]%4`"@"_0`
M4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`?)4GPE>25Y)/V/-&
M9W8LS-XTC)8DY)/R^M`"?\*B_P"K.M$_\+./_P")H`JZW\([H:-=&Q_9`\,P
M7(B;RY;[Q>CP(<<,Z@`E1W&10!X[#X"\9R,L<?P7_9G>1B%"KJH)8]@!]KZF
M@#["_96^#6C?#_P[!KVI^!_!VA^,KV$I>OX;MG2&%"<B)&=W8XXW,",D>@%`
M'G/[57[;G@KX4^([KPEX:T:7Q;XALSLN!#.L5I:OG&QI`&+..ZJOMD&@#RC1
M_P#@H7XRT'Q:FG_$KX0+86QVR216DLL%U#$PR'"3##\<@94'U%`'U3\7_P!H
M/X<?#CX/Z;\1M:U-Y]-URWCN-*MK10UQ?[T#J$4D=B,DD`=S0!\GZ]_P4<\1
MR7KWF@?"*V31X9!&TM[?R.S$\X+)&%0D=N?QH`^B_P!D7]J;P;\<],U1(M.N
MO#NM:';_`&N]TZZD$J>3T,L<@`W*#@'(4@D<<YH`\'T__@HX9O%L6FS?"ZW@
MT][L0-?+K#R%8]^"X1;?+''(4=>E`&?XO_X*.ZM:^/98M#^&5JWA^VG,;)J%
MV\=[,@/7@;8F(_A(;'K0!I?&/_@HHECJEO:_#?P$+RU,4<TE[KDCQ;]P!*I$
MO.!R-Y;!P>,=0#V*X_:NT]?V)E^/4'A=GN!*EF=&FN?+#W!E$;A9=IRH!9@=
MO(&.*`/(/#G_``4>MKJPU634OA+=0W-K;^99V]GJ?G"9\\^8YB7RD`Y+8;Z4
M`=1^R-^W"_Q4^+MGX!\4>"[719]7+BQO;.],B;PI81NK*.2`?F!Z]J`*'Q[_
M`&^C\/OC)XB\$:9\,XM9@T&\-F+YM7,)F=0`_P`@A;&'W`<G.!0!U'[4/[8E
M_P#!N/P;;7/PZAU'4_$NC)JUU:G5#"++<<",'RF+\AADA>G2@#I?A=^U/I.J
M_LLWGQQ\>:"OA;2XKN2TM+*&Z^U2WK+PHCRB99FW`#H`I)(`.`#PG2?^"C>J
M7/C))KCX3^5X6A_X^S;7C37D*$X$@;8J<#^$@9/&X4`=-\%?V]-5^(WQE\/>
M`]/^$L5N-=U&.T^UG62QBB+9>39Y`R50,VW(Z8S0!WG[6W[9_@SX->*)/!^D
MZ'<>*_$MOL-S:P7"PP6N[^"27#'S,$':%/7DB@#R70_^"AOB#2/%<-C\1?A`
M^EV4Q21OL]S(ES#"V<2".5`)./=<X-`'LO[8G[6%A\%M#\&:GHGAJ+Q5#XSM
MI+VW;[<;4+`JQLK_`.K8G<)1C('0T`>/3_\`!1H-\/)]2A^&.S76O/LT-H;]
MWMHH]@;S)9?*7EB2%C4$G8Y)7Y=P!ZW^P+^U'>_'R\US0]>\,V^D:OHT:70D
ML9&:":%FV]&Y5@?<@@]L4`?2M`'SA\9O`?AK3/'=U+'\)?BEXG;4F:]EOM`U
ML+;B1V)9`KW494@]@N,$8]@#E/\`A&?#W_1N_P`<_P#P=Q__`"=0`V;PKX:F
MB>&7]G/XXO'(I5D;6HB&!X((^W=*`//_`(6?!^X'[0VC02_LI6&@>&UU,2PZ
MKJFJ$7,,*G<CM"+AE9QA<@;AF@#[@^).I7>C?#K7M7LHS)=:?I]Q<PJHR2Z1
MLR\#W%`'X[_LD6%CXM_:O\#P^*-4MXH+W7(KR[N+YP$G=6,VQB>"9'4)[EP.
M]`'U9^T5\6?V2/&OQWOX/$OP]\3>,/$,,R:3'>:4ZM#=NIVHL1$P#?,2`<<F
M@#R#_@J:'T?XZ:#X#LX'L]`\)^'+2VTJR8Y\F,@@Y/.X_*%SD_=H`O>//$O@
MOPS_`,$M?"/@?3-1TR\\1^+-5>^OX+:=&F@,<[L6D7[RX58DY_#(H`SOV&X=
M5\)?!KXS_%=T^SZ7;>&GT.WFD0[9[J9U.U#T.T`9]-ZT`<Y_P3:\+V?B;]KK
MPPFI1K)9Z(DVK2JPR,PQDH3_`,#*T`</XH^T_$W]IF]CA5/.\5>)##&%''[R
M?:/T-`'I/_!3?4]-D_:=G\.:,MNEAX0TNUTB-((@@4JFY@<>A;%`'7?M5'_A
M!O\`@GQ\&_AW'*L<^ONVOWD1^\05+(?I^^_2@#(_8L\2?#[P-^S7\9O$NOZS
MIR>(]2TPZ-IVF2RKY\JRQ.H*1GYF&]QDC@!><4`<U_P39T";5?VK_#^IXD6T
M\+PSZO=R!>$2.)@`3T&2P%`'G&EZG:>+/CY!K?BF_2RL]:\0"[U"[ER4B1Y]
M[D^P!_`4`>A?\%%?B#H_Q#_:AU?4_#6JP:IH6D6=OI6GW=N<QND:;GVG^)?-
M>3##@CD9%`'1?MLV&H>#O@!\"_AZ5EM[2'0IM8GC^8+)=3LI8GL2H)QW`<^M
M`$_P,\>?#7P%^P!\1M/DU.RF\=^-IVTQ=."DW'D[556/&`BJTK@YQGCK@4`5
M?^"7&BSW/[15]XG@LQ<R>$=`O=0@4C(\\IY:#TYW-0!Y7\"M%U_XG?M#:+8Q
M>)X=,U[6]0>\&M7RAUCN`KS>8PZ$EEX]R*`/5?C5X'T/Q9\6)-.^('[5VBZ_
MXJM672@5T*_NOFW';"LD,11L,Y'!."2.H(H`H_\`!1R7^Q_BUX8^&BWYNT^&
M_A+3=#DDVE0TJPAV8#W5HS^G:@#J/CY:Z;X&_P""9_PI\,1VD=OJOC34I-=N
M"8_GE1%<[R>N0LT`'L:`/6/^")7AB2/0/'OC211Y=U=6VEP-GH8D:20?^1HO
MRH`^[:`.<^)W@RQ\;^'/['O=6UW2D$BRBYT349;*<$=O,C(.#GD'B@#SW_AG
M#P__`-%)^+/_`(6%Y_\`%4`'_#.'A_\`Z*3\6?\`PL+S_P"*H`CTG]F'P!:?
M$'0_&MYKOC;6=8\.2^=83ZQK\]WY)ZD#>3\I[CO0![/)&KAE<!E88*D<8H`^
M4?BA^P!\(?$WB&YU71=2UGPW]KF,SVEFRO`I)RP16'RCT&<#M0!V/[/G['GP
M?^$_BF#Q/I]E>ZSK5FV^UN]5E#BV;D;D0`*&YZD$CJ,&@#H/VG/V;OAQ\<;>
MWF\4VMS;:O91^5;:K92;)HTR3L(/#+DYP1QV(H`\9\'_`/!.OX5Z;J8N-<\4
M>(M7A4@_9PR0!L=B5&<?3%`'N_Q'^`_@3Q5\!H_A!;6TV@>&(3&8[?2F",H1
MMV,MDG)Y).2222<F@#D/@)^R1\._A)JNMZEX:U+6I+O6],DTMY;J5&:&-R"Q
M0A1AN!S0!@?"O]AOX3^`_B)HGC'3=3\07-YH5TEY!%<SH8S(ARI("CH<'\*`
M(_B3^PQ\+O&_CW6/%VLZ_P")C?ZU=/=3A+A`H9CT'R].U`'RE_P5HUNS;]H7
M2?!NGLJV7@_1(+.-`1\A;YL?4*%H`]/_`&=_V)?`_P`3_P!F+P9XJU?4=3T+
M7M1@DNI[FS(83Q/(3'N5N`0F,$8X-`'U?^SA\!?A]\%?"EUHOA33Y)9-1Q]N
MOKUO,FNL`@!CT"@$_*!CF@#Q]O\`@G[\&&\>MKC7VO?V8TIE_L43J(AEL[=^
M-VSMC.<=Z`)O$7[`_P`&]6\576MM>ZY:_:KDW!L[:6-((P6R$5=O"@<?2@#@
M/^"F'Q(\`:-XDTOX7_$7X27VL:?IUHEWH^KVNH_99%#*$<(=IX!4!E.0=JG'
M`H`^5OBOXF^`"?!BVT?X8^"M;M/$VIW,<VI:AKDPF-I$F3Y4##&=S;23M!PI
M'>@#[3_X)*?!W5_`?PVUCQIXITJXT[4_%<B);VMTFR1+5`2K,IY&YF)P>P%`
M%GXH_P#!/WX2>)O$MQJV@ZIJWAB.ZD,C6%GLDMXR>HC5A\HSVS@=L"@#L/V?
MOV-?A!\*?%=KXHLX-0UK6;')M[C4Y0Z0L?XUC``##L3G%`&9\7_V)/AG\1OB
M/K7C77]?\2C4M;G,\WE3H$3@*JJ-O0*%`SZ4`='\>?V5O`?Q7TSPKIFN:KK=
MI8^#[`V%A;64JJH4A`6.5/S$1H/PH`[;]FWX1>&O@I\.CX.\+37<UFUU)>/+
M=L&D=WP#D@`<!0/PH`[^@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`^1_VD_\`
MDM6N?2'_`-%B@#Z5^$'_`"2SP]_V#X?_`$`4`='0`4`%`'S?_P`%.?\`DWZ+
J_K_7_P!!-`'P?_P3B_Y._P##7_;;_P!!-`'[`4`%`!0`4`%`!0`4`?_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
